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Expression of FGD3 gene as 
prognostic factor in young breast 
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The FGD3 gene works as a cell migration inhibitor and seems to be a promising indicator of outcome in 
some human cancers including breast. In this study, we analysed for the first time the prognostic role 
of FGD3 in young breast cancer patients. We studied the relationship between traditional prognostic 
factors, FGD3 expression and outcome in ≤40 years breast cancer patients. We found that lower FGD3 
expression decreased the probability of disease-free survival (p = 0.042) and overall survival (p = 0.007). 
In a multivariate analysis for overall survival AJCC stage (p = 0.005) and FGD3 expression (p = 0.03) 
resulted independent prognostic factors. Low FGD3 expression increased the risk of death from disease 
(HR 5.73, p = 0.03). Moreover, low FGD3 expression was associated with more widespread lymph node 
involvement (p = 0.04) and a lower FGD3 staining intensity was found in positive-lymph-node patients 
vs negative (p = 0.003) and in patients with ≥10 involved lymph nodes vs <10 (p = 0.05). Our results 
suggest FGD3 to be a significant independent prognostic factor in young breast cancer patients in terms 
of disease-free survival and overall survival. A lower expression increased the risk of recurrence and 
death from disease and was associated with widespread lymph node metastases.
Breast cancer is the most common cancer in women. Mortality is decreasing thanks to earlier detection and 
better adjuvant and neoadjuvant treatment, despite incidence is increasing. Only 5–7% of breast cancers occur in 
≤40-year-old women, except for Latin American women, who present a 15% figure1,2, but incidence is increasing 
in this group too. Young women have generally more aggressive tumours than older women do. They present 
tumours of higher grade, larger size, positive lymph nodes3, a higher proportion of basal-like, HER-2 positive 
tumours and a lower proportion of luminal-A tumours4. As a consequence, young women also present a higher 
risk of recurrence and death5. Although several studies have showed the higher tumour aggressiveness in young 
women, they have not demonstrated the regulatory mechanism, yet. There is a clear need of new prognostic 
factors to better stratify patients, to predict individual outcome among the same histological and molecular sub-
group. For this reason, a number of researches are being carried out to identify new prognostic factors in breast 
cancer patients at all ages6.
One of the most promising new prognostic factors is the expression of FGD3 gene (Facio-Genital Dysplasia 
3 gene), localised on long arm of chromosome 9 (Chr9q22.31), codifying for FYVE, RhoGEF and PH-Domain 
containing protein 3. It has been identified by Hayakawa et al. as a guanine nucleotide exchange factor that targets 
cell division control protein 42 (CDC42), inducing its activation and modifying cell morphology with formation 
of lamellipodia7. As a consequence, it plays an inhibiting role on cell migration in both normal and neoplastic 
cells7. Therefore, a lower FGD3 expression seems to indicate a major risk of cell migration, whereas a higher 
expression seems to indicate a minor risk8. The role of this gene was first identified in 2013 during the Sage 
Bionetwork/DREAM Breast Cancer Prognosis Challenge (BCC), a crowdsourced research study by Margolin 
et al.9, realized to identify genes associated with prognosis in breast cancer, using a data set of 1981 cancer sam-
ples (METABRIC). Cheng et al. found that FGD3 gene was the top-ranked protective gene for breast cancer 
and that silencing FGD3 gene resulted in silencing the adjacent SUSD3 gene, the second top-ranked protective 
gene in the study10,11. A further study by Yang et al. in 201412 analysed the use of a new prognostic test (BCAM 
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test), composed of FGD3-SUSD3 metagene, other seven attractor metagenes (CIN, MES, LYM, END, CD68, 
DNAJB9 and CXCL12), tumour size and positive lymph nodes number. BCAM test was universally applicable in 
all tumour stages and subtypes. The low expression of FGD3-SUSD3 metagene was found to be more associated 
with poor outcome than the lack of ESR1 expression10. A recent study by Willis et al.13 has demonstrated the prog-
nostic role of FGD3 expression in a large cohort of breast cancer patients, compared with other important genes 
associated with proliferation as MKI6714, PCNA15 and AURKA16, regardless of ER status and molecular subtype. 
Lower expression was associated with a higher rate of lymph-node involvement and with decreased disease-free 
survival and overall survival. They also demonstrated its prognostic value in head and neck squamous cell carci-
noma, lung adenocarcinoma, cervical squamous cell carcinoma, bladder urothelial carcinoma and sarcoma. No 
studies so far have specifically investigated the role of FGD3 in young patients with breast cancer.
The current study was undertaken to test the prognostic value of FGD3 expression in a young breast cancer 
population. For this purpose, we analysed and compared the prognostic significance of traditional prognostic 
factors and FGD3 expression in our series of young breast cancer patients in terms of disease-free survival (DFS) 
and overall survival (OS).
Results
Descriptive characteristics. We analysed 60 patients, with an average age of 37.0 (range 21–40 years). 
FGD3 expression was assessed by immunohistochemistry (Fig. 1). Distribution according to FGD3 expression by 
clinical and pathologic characteristics of patients showed no significant difference, except for number of patients 
who underwent to axillary lymphadenectomy, that were significantly more frequent among patients with low 
FGD3 expression. Data are summarised in Table 1.
During the study period, 26 patients (43.3%) experienced recurrence and 10 patients (16.7%) died for the 
disease.
Association between traditional prognostic factors and outcome. We analysed the association of 
the most relevant established prognostic factors for breast cancer with outcome using Cox proportional hazards 
regression analysis. Grade (p = 0.06 on OS), pT stage (p < 0.001 on both DFS and OS), pN stage (p = 0.02 on OS), 
AJCC stage (p = 0.08 on DFS, p = 0.001 on OS) and Ki67 (p = 0.09 on DFS) have confirmed to be significant prog-
nostic factors or to approach the significance (data not shown).
Figure 1. Immunostaining for FGD3 in breast cancer tissue blocks (x400). Note: Staining was (a) undetectable 
(−), (b) low (+), (c) moderate (++), (d) intense (+++).
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Characteristic All % FGD3− % FGD3+ % p
Age, median (range) 37 (21–40) — 36 (21–40) — 37 (26–40) — —
Grade
G1 6 10.5 — — 6 10.5 0.14
G2 18 31.6 6 10.5 12 21.1
G3 33 57.9 14 24.6 19 33.3
Total 57 100.0 20 35.1 37 64.9
LVSI
Yes 32 53.3 8 13.3 20 33.3 0.42
No 28 46.7 13 21.7 19 31.7
Total 60 100.0 21 35.0 39 65.0
Molecular Subtype
Luminal A 29 59.2 8 16.4 21 42.9 0.78
Luminal B 9 18.4 4 8.2 5 10.2
Her2+ 3 6.1 1 2.0 2 4.1
Triple negative 8 16.3 2 2.0 6 12.2
Total 49 100.0 15 30.6 34 69.4
Ki67
<15% 14 26.9 6 11.5 8 15.4 0.51
≥15% 38 73.1 11 21.2 27 51.9
Total 52 100.0 17 32.7 35 67.3
AJCC stage
I 26 43.3 7 11.7 19 31.7 0.16
II 15 25.0 6 10.0 9 15.0
III 12 20.0 3 5.0 9 15.0
IV 7 11.7 5 8.0 2 3.3
Total 60 100.0 21 35.0 39 65.0
Primary tumour surgery
BCS 31 51.7 12 20.0 19 31.7 0.60
Mastectomy 29 48.3 9 15.0 20 33.3
Total 60 100.0 21 35.0 39 65.0
Axillary lymph node surgery
SLB neg 20 33.3 3 5.0 17 28.3 0.02
SLB pos + AD 40 66.7 18 30.0 22 36.7
Total 60 100.0 21 35.0 39 65.0
Neoadjuvant Chemotherapy
Yes 19 31.7 8 13.3 11 18.3 0.56
No 41 68.3 13 21.7 28 46.7
Total 60 100.0 21 35.0 39 65.0
Adjuvant Chemotherapy
Yes 39 65.0 13 21.7 26 43.3 0.78
No 21 35.0 8 13.3 13 21.7
Total 60 100.0 21 35.0 39 65.0
Hormonotherapy
Yes 38 63.3 15 25.0 23 38.3 0.41
No 22 36.7 6 10.0 16 26.7
Total 60 100.0 21 35.0 39 65.0
Trastuzumab
Yes 10 16.7 4 6.7 6 10.0 0.73
No 50 83.3 17 28.3 33 55.0
Total 60 100.0 21 35.0 39 65.0
Adjuvant Radiotherapy
Yes 37 61.7 14 23.3 23 38.3 0.59
No 23 38.3 7 11.7 16 26.7
Total 60 100.0 21 35.0 39 65.0
Table 1. Clinical and pathologic characteristics of patients: overall and according to FGD3 expression. 
Abbreviations: LVSI, lympho-vascular space invasion; AJCC stage, The American Joint Committee on Cancer 
staging; BCS, breast conservative surgery; SLB, sentinel lymph node biopsy; AD, axillary dissection.
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Association between FGD3 expression and outcome. Concerning FGD3, among 60 analysed sam-
ples, 21 (35%) showed low FGD3 expression and 39 (65%) showed high FGD3 expression. To compare the dis-
tribution of recurrence and death from disease between the two groups, a Fisher’s Exact Test was carried out 
(Table 2). Recurrence and death from disease were significantly higher among patients with low FGD3 expres-
sion, (p = 0.003 and p = 0.001, respectively). Moreover, using KM method, we found that patients with low FGD3 
expressing tumours had significantly reduced DFS (p = 0.042) and OS (p = 0.007) (Fig. 2). In addition, we eval-
uated the impact of FGD3 expression on outcome according to year of diagnosis, comparing patients diagnosed 
before or after 2008, to exclude the possible interference on prognosis due to more effective treatments in the 
latter period. High-FGD3-expressing patients displayed significantly more favourable outcome in both cohorts 
of patients (data not shown).
Multivariate analysis. Table 3 shows the results of multivariate Cox proportional hazards regression analy-
sis in which AJCC stage (I-II vs III-IV), FGD3 expression and tumour grade were tested simultaneously to assess 
the risk ratio for death from disease and the independence of each variable. A higher AJCC stage (III-IV) was 
the strongest independent predictor of poor outcome (HR = 9.36, p = 0.005). The second stronger independent 
predictor of poor outcome was FGD3 expression (HR = 5.73, p = 0.03). On the contrary, tumour grade was not a 
significant predictor of prognosis by multivariate analysis.
FGD3 
Expression Recurrence Total % p
Death 
from 
disease Total % p
Low








12 39 30.8 2 39 5.1
Total 27 60 100.0 10 60 100.0
Table 2. Association between FGD3 expression and recurrence/death from disease.
Figure 2. Disease-free survival and overall survival according to FGD3 expression. Note: (a) Disease-free 
survival; (b) Overall survival.
Parameters
Overall survival
HR 95% CI P
AJCC stage
I-II Ref.
III-IV 9.36 1.98–44.22 0.005
FGD3 expression
High Ref.
Low 5.73 1.20–27.32 0.03
Grading
G1-G2 Ref.
G3 2.76 0.58–13.21 0.2
Table 3. Multivariate Cox analysis for death from disease.
5Scientific RepoRtS |         (2019) 9:15204  | https://doi.org/10.1038/s41598-019-51766-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
Association between FGD3 expression and outcome stratified by AJCC stage and molecular 
subtype. We stratified our population by AJCC stage, identifying patients with low AJCC stage (I-II) and 
high AJCC stage (III-IV), and we analysed the association of FGD3 expression with outcome in the two groups 
by Kaplan-Meier method, as shown in Fig. 3. In terms of OS, patients with stage I-II AJCC and high FGD3 
expression were all alive at 10 years of follow-up, while 10 of the 13 patients with stage I-II and low FGD3 expres-
sion (76.9%) were alive at 10 years. Patients with stage III-IV AJCC and high FGD3 expression had a quite bet-
ter prognosis than those with low stage and low FGD expression and a much better prognosis than patients 
with stage III-IV AJCC and low FGD3 expression (p < 0.001). The significance was only approached in terms 
of DFS (p = 0.08), but in each AJCC stage group, patients with high FGD3 expression had longer DFS at 10 
years than those with low FGD3 expression. Again, high-FGD3-expressing patients with stage III-IV had a better 
outcome compared to low-FGD3-expressing patients with stage I-II. Similarly, we stratified our population by 
molecular subtype and we analysed the association of FGD3 expression with outcome in each subtype. Again, 
high-FGD3-expressing patients had a more favourable outcome, both in terms of DFS and OS (p = 0.018 and 
p < 0.001, respectively) (data not shown). In addition, we adjusted the analysis by AJCC stage and immunohisto-
chemical subtype and found that FGD3 expression retained its significance (p = 0.02 and p = 0.006, respectively).
Association between FGD3 expression and lymph node involvement. We analysed FGD3 expres-
sion and lymph node involvement using Fisher’s Exact Test (Table 4). We found that low FGD3 expressing 
patients had higher incidence of lymph node metastases as compared with high FGD3 expressing ones, (61.9% 
versus 41.0%), but the difference was not significant (p = 0.12). However, among patients with low FGD3 expres-
sion there was a significantly higher incidence of massive lymph nodal spread (≥10 positive lymph nodes) 
(61.5% versus 25.0%; p = 0.04). Finally, we analysed the distribution of FGD3 expression staining intensity 
(from – to + + + ) in lymph node negative patients (n = 31) and lymph node positive ones (n = 29) using a Chi 
Square Test: the distribution was significantly different (p = 0.007) and there was an increasing rate of positive 
lymph nodes as FGD3 staining intensity decreased, using Chi Square Test for Trend (p = 0.003). Similarly, among 
patients with positive lymph nodes, there was a difference in distribution of FGD3 staining intensity in patients 
with <10 positive lymph nodes (n = 22) and ≥10 positive lymph nodes (n = 12) (p = 0.05) and a Chi Square 
Test for Trend revealed an increasing in lymph node number involvement as FGD3 staining intensity decreased 
(p = 0.01) (data not shown).
Figure 3. Disease-free survival and overall survival according to FGD3 expression in AJCC stage stratified 
groups. Note: (a) Disease-free survival; (b) Overall survival. Abbreviations: I-II, FGD3+ = I-II AJCC stage with 
high FGD3 expression; I-II, FGD3− = I-II AJCC stage with low FGD3 expression; III-IV, FGD3+ = III-IV 
AJCC stage with high FGD3 expression; III-IV, FGD3− = III-IV AJCC stage with low FGD3 expression.
FGD3 Expression N + Total % p pN+ ≥ 10 Total % p
Low
(0% - or ≤30%+) 13 21 61.9
0.12
8 13 61.5
0.04High(>30%+ or ++ or 
+++)
16 39 41.0 4 16 25.0
Total 29 60 100.0 12 29 100.0
Table 4. Association between FGD3 expression and lymph node involvement.
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Discussion
We found a high prevalence of classical predictors of poor outcome in our series of young breast cancer patients. 
So, our findings confirmed the increased breast cancer aggressiveness in young patients as compared to general 
population. Hence, more than half of patients had G3, multifocal/multicentric tumours with lymphovascular space 
invasion. One third of tumours was >2 cm at diagnosis (≥pT2 stage). Nearly half of patients had positive lymph 
nodes, with a half of them having >3 involved lymph nodes (pN2 - pN3). Metastases at diagnosis were present in a 
relatively high percentage of cases. These figures were in accordance with a study by Gnerlich et al.3 reporting higher 
percentages of G3 tumours (56% vs 26%), >2 cm lesions and involved lymph nodes (38% vs 25%) among young 
women. Compared to general population, in the current series we found a higher percentage of Her2 + tumours 
(24.5% vs 13–15%1) and triple negative tumours (16.3% vs 11.2%17), whereas the incidence of ER/PgR + tumours 
was similar (77.6% vs 80%). Our findings are in accordance to Anders et al.17 study, which showed a higher preva-
lence of Her2 + (52% vs 24%) and triple negative tumours (7% vs 2.6%) among young women compared to older 
women, but differed from it about the incidence of ER/PgR + tumours, which resulted lower in younger patients 
compared to older ones in Anders et al.’s study (71% vs 80%). As a consequence of multicentric and large size disease, 
in our series there was a higher percentage of mastectomy (48.3%) and a lower percentage of conservative operations 
(51.7%), compared to older women in whom percentages are 14% vs 86%, respectively18. This result shows that in 
clinical practice there is a frequent recourse to mastectomy in a group of patients in which we would theoretically 
prefer to use conservative operations, to preserve psychological and functional aspects.
Traditional prognostic factors confirmed their influence on outcome in the current series. According to lit-
erature, the significance was achieved by tumour grade19 on OS, pT stage20 on DFS and OS, pN stage20 on OS, 
AJCC stage on OS. The failure to reach significance of universally approved prognostic factors in some subgroup 
analysis was probably due to the limited number of cases.
The most important finding of our study was the prognostic role of FGD3 expression on both DFS and OS, 
despite the relatively small number of cases, in accordance with previous studies who analysed patients not selected by 
age9,10,12,13. Concerning the choice of the cut-off for analysis of IHC FGD3 expression, a similar approach has been used 
in several immunohistochemical studies21,22. Moreover, the chosen cut-off point seems to be in accordance with Willis 
et al.’s one, as they talked about “high expression” and not about percentage of positive cells or staining intensity only13. 
We found that low FGD3 expression was associated with recurrence: patients with low FGD3 expression relapsed sig-
nificantly more frequently than those with high FGD3 expression. Moreover, patients with low FGD3 expression had a 
significantly higher percentage of death from disease. Thus, we found that low FGD3 expression had a significant neg-
ative effect on disease-free survival and overall survival. Our result is in accordance with the FGD3 gene inhibiting role 
on cell migration, which was demonstrated in other studies7. Interestingly, our results indicate that FGD3 expression 
represents an independent predictor of clinical outcome in young breast cancer patients in terms of OS, second only to 
high AJCC stage (III-IV), according to literature23. Whereas, a well-known risk factor such as tumour grade, was not 
found to be significant and independent. This is an interesting finding, considering the poorer outcome of young breast 
cancer patients and the failure in identifying this higher risk subgroup by traditional predictors. Indeed, the introduc-
tion of new prognostic factors such as FGD3 expression could help selecting patients at higher risk. This could influence 
the choice of individual treatment and possibly translate into improved outcome.
Another relevant finding was that stratification by FGD3 expression within two subgroups of different 
AJCC stage23 (stage I-II AJCC vs stage III-IV AJCC) identified patients with different outcome within the same 
AJCC stage subgroup. In particular, we found that low FGD3 expression significantly worsen the prognosis of 
patients in the same AJCC stage. Furthermore, according to our results, it seems that FGD3 expression exceeds 
the strength of AJCC stage in determining patients’ outcome. In fact, patients with advanced disease (stage 
III-IV AJCC) and high-FGD3-expression did better than patients with early stage disease (stage I-II AJCC) but 
low-FGD3-expression (Fig. 3). This result suggests that biological features of the tumour such as FGD3 expression 
may represent an even stronger determinant of survival than the classical tumour stage.
Previous studies7,13 pointed out the inhibiting role of FGD3 on cellular migration and its influence in lymph 
node metastases. Therefore, we studied the association between FGD3 expression and lymph node involvement 
in our series. We found that lower FGD3 expression was significantly associated with a more widespread lymph 
node involvement (Table 4). Moreover, FGD3 staining intensity was significantly higher in patients without 
lymph node involvement compared to those with involved lymph nodes. Conversely, the FGD3 staining intensity 
among patients with ≥10 positive lymph nodes was significantly lower than that of patients with <10 positive 
lymph nodes. This finding further suggests an association between lower FGD3 expression and lymph node 
involvement, in accordance with previous studies7,13. So, the evaluation of FGD3 expression could be helpful to 
estimate the risk of lymph node involvement in patients without clinical evidence of metastasis.
Willis et al.13 have recently demonstrated by RT-qPCR that estradiol stimulation increases FGD3 mRNA expres-
sion level, through the ESR1 binding site within the gene. This interesting finding may introduce the hypothesis of 
a potential role for FGD3 as a therapeutic target, in addition to its prognostic role. Hence, the Collaborative Group 
on Hormonal Factors in Breast Cancer reported in two different studies that both oral contraceptive24 and hormonal 
replacement therapy25 increased the risk of breast cancer due to oestrogen stimulation. On the other hand, these 
same studies observed that oestrogen-induced breast cancers were less aggressive than general population’s breast 
cancers. Therefore, we might now hypothesize that FGD3 may have a role in this mechanism: oestrogen stimulation 
could increase FGD3 expression, which in turn may determine a better prognosis in oestrogen treated patients. Our 
results seems to confirm that high FGD3 expression is a protective factor against recurrence and death from dis-
ease. Considering the relatively small number of patients in this study, our results must be interpreted with caution. 
Therefore, further studies on FGD3 in breast cancer are warranted to evaluate both its prognostic significance and to 
explore the possibility of modulating this gene expression for therapeutic purposes.
The current study confirmed the higher breast cancer aggressiveness in younger women. We found that FGD3 
expression was a significant and independent predictor of clinical outcome. In particular, high FGD3 expression was 
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a protective factor against recurrence, death from disease and lymph node involvement. FGD3 expression allowed to 
distinguish patients with significantly different clinical fate within the same AJCC stage, with the role of FGD3 possibly 
being stronger than that of AJCC stage in determining outcome. Our findings in young women are in line with those 
of previous studies in breast cancers not selected by age9,10,12,13. To our knowledge, this is the first study to investigate 
the role of FGD3 expression using a simple and inexpensive method such as IHC and reporting significant differences 
in clinical outcome even with a relatively small number of patients. This represents an example of the possible useful-
ness of introducing FGD3 assessment at the clinical level to translate the advances from previous studies on very large 
cohorts of patients and using more sophisticated techniques in the everyday practice of a single institution.
Methods
Patients selection and data collection. We identified 60 ≤ 40-year-old women suffering from breast can-
cer, surgically treated and followed between 1998 and 2018 at the Breast Unit of the Gynaecology and Obstetrics 
Department, Careggi Hospital, University of Florence. We collected patients’ data from medical records, includ-
ing surgical treatment of primary tumour and axillary lymph nodes, neoadjuvant and adjuvant treatment, clinical 
and pathological characteristics of tumours, disease-free survival and overall survival. After surgery, patients had 
follow up visits every 6 months during the first 5 years and every year, thereafter. Mammogram and ultrasound 
scan of the breast were performed every 12 months. Average follow up interval was 92.5 months (range 8–168 
months). All patients gave their written informed consent to the use of tissue blocks for the study purposes. The 
study was approved by the local ethics committee (Careggi Hospital, University of Florence).
FGD3 expression. Immunohistochemical evaluation of FGD3 expression was performed on slides hours to days 
after deep sectioning of formalin-fixed, paraffin embedded tissue blocks. Slides were stored at 4 °C in order to test pos-
sible antigen recovery. In addition, antigen preservation was verified prior to FGD3 analysis by immunohistochemistry 
with internal positive anatomic controls. The use of this procedure prevented proteolytic degradation of the samples, 
because it is known that formalin-fixed tissue within paraffin blocks maintain intact protein structures for even more 
than 20 years, in contrast with old slides in which proteolytic degradation may occur after some years. FGD3 protein 
expression was evaluated using a rabbit polyclonal antibody against FGD3 at a dilution of 1:750 (Sigma-Aldrich, St. 
Louis, MO, Cat# SAB1401929, RRID:AB_10609712). Paraffin removing, antigen recovery and antibody incubation 
were carried out using Bench Mark Ultra device, according to a set protocol. The protein expression was evaluated 
using the detection system HRP ultra View Universal DAB Detection Kit (Ventana, Tucson, Arizona). Positive con-
trol was obtained using tonsillar tissue. Negative control was obtained using a rabbit serum antibody (Normal, Dako 
Agilent, Carpinteria, CA, Cat# A020602, RRID:AB_578507). The results were expressed as percentage of positive cells 
and as staining intensity (undetectable−, weak+, moderate++, strong+++), as shown in Fig. 1.
Cellular reactivity cut-off point. To evaluate the prognostic value of FGD3 expression, we compared the 
patients’ disease-free survival and overall survival after dividing them into two groups according to different 
cut-off points. The P values were significant for DFS (p = 0.04) and OS (p = 0.007) when we arbitrarily divided 
our population in low-FGD3-expressing tumours (undetectable staining or weak staining with ≤30% positive 
cells) and high-FGD3-expressing tumours (all other cases: strong or moderate staining, or weak staining with 
>30% positive cells). The level of significance decreased or was not achieved if we considered only the percentage 
of positive cells, with different cut-off points, or the staining intensity.
Statistical analysis. The frequency distribution was assessed by Fisher’s Exact Test or Chi-Square Test, as appro-
priate. Chi Square Test for Trend was used to analyse the linear increasing trend of FGD3 staining intensity between two 
subgroups based on lymph node involvement. Disease-free interval and overall survival were calculated according to 
Kaplan-Meier method and evaluated by Log-Rank Test. Univariate Cox proportional hazards regression analysis was 
used to evaluate the effect of each prognostic factor on disease-free survival and overall survival. We used a multivariate 
Cox proportional hazards regression analysis, with forward selection of variables, to assess the independence of each 
prognostic variable. Data analysis was performed using IBM SPSS Statistics, version 17.0.
Ethical approval. All procedures performed in this retrospective study involving human participants were 
in accordance with the ethical standards of the institutional research committee and with the 1964 Helsinki dec-
laration and its later amendments or comparable ethical standards. This article does not contain any studies with 
animals performed by any of the authors.
Informed consent. Informed consent was obtained from all individual participants included in the study.
Data availability
The datasets during and/or analysed during the current study are available from the corresponding author on 
reasonable request.
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